Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® today ... Caris Molecular Intelligence®, the company,s panomic, comprehensive tumor ... between several rare and difficult to treat gynecological ... the potential to improve patient outcomes. These studies ... the Society of Gynecologic Oncology (SGO) 2015 Annual ...
(Date:3/29/2015)... As a symbol of its commitment to meet ... clients, Whitehouse Laboratories is excited to announce that is ... for the 2015 race season. Success on the race ... sense of precision and attention to detail. These are ... quality control testing laboratory. Sponsorship of the race car, ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3
... , ANNAPOLIS, Md., Oct. 5 PharmAthene, Inc. ... developing medical countermeasures against biological and chemical threats, ... Officer, David P. Wright and Dr. Valerie Riddle, ... the Homeland Security Television Channel (HSTV) 30-minute documentary ...
... RICHMOND, Calif., Oct. 5 Sigma-Aldrich Corporation (Nasdaq: ... SGMO ) today announced a major expansion ... exclusive rights to develop and distribute zinc finger ... production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed ...
... ... paper on Organic Electronics that discusses rfid tags, OLED, AM OLED, PM OLED, electroluminescence, ... ... white paper that discusses the current state of the organic electronics (OE) market, including ...
Cached Biology Technology:PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security 2PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security 3Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 2Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 3Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 4Free Organic Electronics White Paper Discusses Rfid Tags, OLED, AM OLED, PM OLED, Electroluminescence, e-Paper, OE Market Forecast 2
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
(Date:3/11/2015)... March 11, 2015   The Sync Project™ ... to scientifically measure and harness music to improve ... biometrics and objective measurements of physiology, enabling the ... scale in large populations. It is designed for ... clinicians perform rigorous studies and accelerate the discovery ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... for a better anti-itch remedy" Your wish may soon ... of Medicine in St. Louis have identified the first ... system. The discovery could rapidly lead to new treatments ... severe itching. , The "itch gene" is GRPR (gastrin-releasing ...
... cell know to send the signal that announces a smoker’s ... answer appears to be sugar. , A University of ... online proposes a role for sugar as the hinge that ... of nicotine’s arrival. , Structural biologist Raymond Stevens of ...
... pan out. Neither did two other potential anti-aging agents. ... is now a front- runner in ongoing animal experiments ... inflammation, cancer and other destructive processes, can boost the ... meeting of the American Aging Association, University of Michigan ...
Cached Biology News:Scratch no more: Gene for itch sensation discovered 2Scratch no more: Gene for itch sensation discovered 3Nicotine rush hinges on sugar in neurons 2Agent slows aging in mice 2
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
...
...
...
Biology Products: